Results 161 to 170 of about 20,413 (188)

Case Report: Severe SIADH and QTc prolongation induced by escitalopram-quetiapine interaction in a CYP2C19 intermediate metabolizer at therapeutic doses. [PDF]

Front Pharmacol
Jiang Z, Qu X, Yan Z, Fang J, Lan J, Zhao X, Qi W.   +6 more
europepmc   +1 more source

Self-Reported Pharmacogenetic Medication Use in the Our Future Health Cohort. [PDF]

Clin Transl Sci
Dixon P, Newman WG, Sharma V, McDermott JH, Wright Drakesmith C.   +4 more
europepmc   +1 more source

An Exploratory, Retrospective Study of the CYPRI Score for Pharmacogenetic Testing Among Mental Health Patients. [PDF]

Genes (Basel)
Comtesse SM, Tašková I, Safářová N, Hahn M.   +3 more
europepmc   +1 more source

Exploring the roles of cytochrome P450 enzymes and their inhibitors in cancers and non-neoplastic human diseases. [PDF]

Arch Pharm Res
Lee H, Kwon YJ, Chun YJ.
europepmc   +1 more source

Association of Clopidogrel Genetic Polymorphism With Efficacy and Safety for Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Updated Meta-Analysis. [PDF]

J Clin Neurol
Park H, Jung YH, You S, Yun J, Kim YH, Chang Y, Park MS, Song TJ, Lee KY.   +8 more
europepmc   +1 more source

Unraveling enantioselective metabolism: Human cytochrome P450s in arachidonic acid biotransformation. [PDF]

Drug Metab Dispos
Isse FA, El-Sherbeni AA, El-Kadi AOS.
europepmc   +1 more source

Revisiting the Proton Pump Inhibitor-Clopidogrel Conundrum: Do PPIs Truly Worsen Cardiovascular Outcomes? [PDF]

JACC Asia
Bavishi C, Hirai T.
europepmc   +1 more source

Confounding Effect of Hepatic Carboxylesterase 1 (CES1) Variability on Clopidogrel Oxidation. [PDF]

Mol Pharm
Subash S, Singh DK, Khojasteh SC, Murray BP, Zientek MA, Jones RS, Kulkarni P, Smith BJ, Prasad B.   +8 more
europepmc   +1 more source

Correction to "Genotype-Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers". [PDF]

Clin Transl Sci
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CYP2C19 gene polymorphism in Ningxia

Pharmacological Reports, 2023
Poor metabolizer (PM) status of CYP2C19 can be a predisposing factor for developing gastric cancer in H. pylori-infected patients. It is unclear whether PM status of CYP2C19 can also be a potential factor for H.pylori infection in healthy people.We used high-throughput sequencing to detect single nucleotide polymorphisms (SNPs) at just three loci ...
Zhen Yang, Yunqian Xie, Daya Zhang, Yan Zou, Ximei Li, Runxiang Chen, Xiaodong Zhang, Shiju Chen, Feihu Bai   +8 more
openaire   +2 more sources